AB009. Targeting the stratification of neuroblastoma: clinical and biological challenges

Abstract

Background

Neuroblastoma (NB) is a solid tumor derived from the sympathoadrenal lineage of the neural crest, and is one of the lowest survival rates in pediatric Vietnamese patients. This is a complex types of cancer because clinical features and genetic diversity heterogeneous. The NB treatment is mostly determined by clinical and biological assessment to classify the patients with low- and high-risk under the guideline of SOPIEN/COG protocols.

Objective

We validate the clinical presentations and biological markers that might assist the clinical decision-making process to improve the survival rates in NB at the Children Hospital II, Hochiminh city.

Methods

RNA and genomic DNA were extracted from 65 cases of NB tumor tissues from the Children Hospital II. We assessed the study of molecular-based genotyping, FISH, and mRNA expression to identify the biomarkers including TrkA, MYCN gene amplification, segmental chromosome aberrations (loss of heterozygosity 1p, 11q, or gain of 17q), and compare with clinical presentations are classified as: age at diagnosis, histology, and INSS stages.

Results and conclusions

We identify amplification of MYCN in 12 out of 65 (18.46%) NB patients, and chromosome aberrations in 5 out of 65 (7.69%). Additionally, reduced or induced TrkA was correlated with amplified and non amplified MYCN respectively. Together, our study supports the pipeline for risk stratification of Vietnamese NB and supports the therapeutics of the disease.